培门冬酰胺酶治疗结外NK/T细胞淋巴瘤的效果和安全性

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (31 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨培门冬酰胺酶治疗结外NK/T细胞淋巴瘤的效果和安全性。方法选取鞍山市肿瘤医院2014年1月～2017年12月收治的60例结外NK/T细胞淋巴瘤患者作为研究对象，以随机数字表法分为对照组及观察组，每组各30例。对照组采用吉西他滨、奥沙利铂、地塞米松与左旋门冬酰胺酶治疗，观察组采用吉西他滨、奥沙利铂、地塞米松与培门冬酰胺酶治疗，比较两组患者的近期疗效及药物毒副反应。结果观察组的总有效率为93.33%，对照组的总有效率为90.00%，两组比较差异无统计学意义（P＞0.05）。观察组的消化道反应、高血糖及变态反应发生率明显低于对照组（P＜0.05）。两组患者的粒细胞减少、血小板减少、肝功能损害发生率比较，差异无统计学意义（P＞0.05）。结论培门冬酰胺酶治疗结外NK/T细胞淋巴瘤近期效果确切，毒副反应较小，安全性高，值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	金莉
	李朝辉
	徐宁
	宋楠

关键词 ：培门冬酰胺酶, NK/T细胞淋巴瘤, 近期效果, 安全性

Abstract：Objective To investigate the effect and safety of Pegaspargase in the treatment of extranodal NK/T cell lymphoma.Methods A total of 60 patients admitted from January 2014 to December 2017 in Anshan Tumor Hospital were selected as the research objects.Patients were divided into the control group and the observation group by the random table method,30 cases in each group.The control group was treated with Gemcitabine,Oxaliplatin,Dexamethasone and L-asparaginase,while the observation group was treated with Gemcitabine,Oxaliplatin,Dexamethasone and Pegaspargase.The short-term curative efficacy and drug toxicity side effect were compared between the two groups.Results The total effective rate was 93.33%in the observation group and 90.00%in the control group,the difference was not statistically significant(P＞0.05).The incidence of digestive tract reaction,hyperglycemia and allergic reaction in the observation group was significantly lower than that in the control group (P＜0.05).There was no significant difference in the incidence of neutropenia,thrombocytopenia and hepatic dysfunction between the two groups(P＞0.05).Conclusion Pegaspargase in the treatment of extranodal NK/T cell lymphoma is effective in the short term,with less side effect and high safety.It is worthy of clinical promotion.

Key words： Pegaspargase NK/T cell lymphoma Short-term effect Safety

引用本文:

金莉；李朝辉；徐宁；宋楠. 培门冬酰胺酶治疗结外NK/T细胞淋巴瘤的效果和安全性[J]. 中国当代医药, 2019, 26(2): 74-76.
JIN Li；LI Zhao-hui；XU Ning； SONG Nan. Effect and safety of Pegaspargase in the treatment of extranodal NK/T-cell lymphoma. 中国当代医药, 2019, 26(2): 74-76.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2019/V26/I2/74

[1]	Reyes VE，Al-Saleem T，Robu VG，et al.Extra nodal NK/TCell lymphoma nasal type：efficacy of pegaspargase report of two patients from the united sates and review of literature[J].Leuk Res，2010，34（1）：50-52.
[2]	Zhou Z，Li Z，Sun Z，et al.S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine[J].Sci Rep，2016，6（29）：23-25.
[3]	Tse E，Kwong YL.The diagnosis and management of NK/T-cell lymphomas[J].J Hematol Oncol，2017，4（14）：85-88.
[4]	Wang J，Wang L，Liu C，et al.Efficacy of combined gemcitabine，oxaliplatin and pegaspargase （P-gemox regimen） in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma[J].Oncotarget，2016，7（20）：29 092-29 101.
[5]	Wang J，Wang H，Wang Y，et al.Analysis of the efficacy and safety of a combined gemcitabine，oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J].Oncotarget，2016，7（23）：35 412-35 422.
[6]	Lahoud OB.High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma[J].Am J Hematol，2018，6（1）：40-46.
[14]	Kallberg E，Vogl T，Liberg D，et al.S100A9 interaction with TLR4 promotes tumor growth[J].PLoS One，2012，7（3）：34 207-34 208.
[7]	Sun Y，Narayan VA，Wittenberg GM.Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders[J].BMC Pharmacol Toxicol，2016，10（21）：47-49.
[8]	Zhang L，Jia S，Ma Y，et al.Efficacy and safety of cisplatin，dexamethasone，gemcitabine and pegaspargase （DDGP） regimen in newly diagnosed，advanced-stage extranodal natural killer/T-cell lymphoma：interim analysis of a phase 4 study NCT01501149[J].Oncotarget，2016，7（34）：55 721-55 731.
[9]	Zhang L，Li S，Jia S，et al.The DDGP （cisplatin，dexamethasone，gemcitabine，and pegaspargase） regimen for treatment of extranodal natural killer （NK）/T-cell lymphoma，nasal type[J].Oncotarget，2016，7（36）：58 396-58 404.
[10]	Xu PP，Xiong J，Cheng S，et al.A phase Ⅱ study of Methotrexate，Etoposide，Dexamethasone and Pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed，stageⅠE toⅡE extranodal natural-killer/T-cell lymphoma，nasal-type[J].EBioMedicine，2017，25（1）：41-49.
[11]	Chang Y，Fu X，Sun Z，et al.Utility of baseline，interim and end-of-treatment（18）F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J].Sci Rep，2017，7（24）：41 057-41 059.
[12]	Liang J，Wang L，Peter Gale R，et al.Efficacy of pegaspargase，etoposide，methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA[J].Blood Cancer J，2017，7（9）：60-63.
[13]	Bu S，Yuan F，Wei X，et al.L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma[J].Exp Ther Med，2016，11（6）：2437-2445.
[15]	Gery S，Gombart AF，Yi WS，et al.Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia[J].Blood，2005，106（8）：2827-2836.